The Drive to Discover. The Experience to Deliver. Contact Us Press Releases E-mail Alerts About Incyte R&D Jakafi® (ruxolitinib) Disease Education Investors Careers INCYTE Incyte 2014 Annual Report to Stockholders Jakafi® (ruxolitinib) Prescribing Information is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. News Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis View press release MPN Awareness Day Raises Awareness and Support for the Nearly 300,000 People in the United States Affected by Rare Blood Cancers View press release Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody View press release Jakafi® (ruxolitinib) Prescribing Information www.jakafi.com/hcp/ Jakafi Facebook Page To learn more, click here. IncyteCARES Connecting to Access, Reimbursement, Education and Support To learn more, click here Secondary menu The Drive to Discover. The Experience to Deliver. Privacy Legal Notices © 2012 - 2015 Incyte Corporation. All Rights Reserved. Opt-Out Cookie Policy